Advertisement

Topics

Migraine Treatment Receives EMA Regulatory Filing Acceptance

09:56 EDT 21 Jun 2017 | PharmPro

Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance. It is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance.
Contributed Author: 
Novartis Pharmaceuticals Corp.

Original Article: Migraine Treatment Receives EMA Regulatory Filing Acceptance

NEXT ARTICLE

More From BioPortfolio on "Migraine Treatment Receives EMA Regulatory Filing Acceptance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...